1. Home
  2. AVXL vs RYI Comparison

AVXL vs RYI Comparison

Compare AVXL & RYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • RYI
  • Stock Information
  • Founded
  • AVXL 2004
  • RYI 1842
  • Country
  • AVXL United States
  • RYI United States
  • Employees
  • AVXL N/A
  • RYI N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • RYI Metal Fabrications
  • Sector
  • AVXL Health Care
  • RYI Industrials
  • Exchange
  • AVXL Nasdaq
  • RYI Nasdaq
  • Market Cap
  • AVXL 794.0M
  • RYI 699.3M
  • IPO Year
  • AVXL N/A
  • RYI N/A
  • Fundamental
  • Price
  • AVXL $10.70
  • RYI $23.20
  • Analyst Decision
  • AVXL Strong Buy
  • RYI Hold
  • Analyst Count
  • AVXL 2
  • RYI 1
  • Target Price
  • AVXL $44.00
  • RYI $25.00
  • AVG Volume (30 Days)
  • AVXL 890.2K
  • RYI 241.4K
  • Earning Date
  • AVXL 08-05-2025
  • RYI 07-29-2025
  • Dividend Yield
  • AVXL N/A
  • RYI 3.23%
  • EPS Growth
  • AVXL N/A
  • RYI N/A
  • EPS
  • AVXL N/A
  • RYI N/A
  • Revenue
  • AVXL N/A
  • RYI $4,495,200,000.00
  • Revenue This Year
  • AVXL N/A
  • RYI $0.35
  • Revenue Next Year
  • AVXL N/A
  • RYI $3.40
  • P/E Ratio
  • AVXL N/A
  • RYI N/A
  • Revenue Growth
  • AVXL N/A
  • RYI N/A
  • 52 Week Low
  • AVXL $4.00
  • RYI $17.18
  • 52 Week High
  • AVXL $14.44
  • RYI $27.41
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 74.00
  • RYI 62.14
  • Support Level
  • AVXL $9.08
  • RYI $21.22
  • Resistance Level
  • AVXL $9.78
  • RYI $22.39
  • Average True Range (ATR)
  • AVXL 0.51
  • RYI 0.90
  • MACD
  • AVXL 0.14
  • RYI 0.29
  • Stochastic Oscillator
  • AVXL 93.36
  • RYI 99.17

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority revenue is generated from the United States.

Share on Social Networks: